These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 33116362)

  • 1. Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients.
    Ruangvaravate N; Choojun K; Srikulsasitorn B; Chokboonpiem J; Asanatong D; Trakanwitthayarak S
    Clin Ophthalmol; 2020; 14():3109-3119. PubMed ID: 33116362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment.
    Oddone F; Kirwan J; Lopez-Lopez F; Zimina M; Fassari C; Holló G;
    Adv Ther; 2022 Aug; 39(8):3501-3521. PubMed ID: 35524840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy.
    Konstas AG; Boboridis KG; Kapis P; Marinopoulos K; Voudouragkaki IC; Panayiotou D; Mikropoulos DG; Pagkalidou E; Haidich AB; Katsanos A; Quaranta L
    Adv Ther; 2017 Jan; 34(1):221-235. PubMed ID: 27913991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials.
    Uusitalo H; Egorov E; Kaarniranta K; Astakhov Y; Ropo A
    Clin Ophthalmol; 2016; 10():445-54. PubMed ID: 27041987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of preservative-free tafluprost on tear film osmolarity, tolerability, and intraocular pressure in previously treated patients with open-angle glaucoma.
    Janulevičienė I; Derkač I; Grybauskiene L; Paulauskaitė R; Gromnickaite R; Kuzmienė L
    Clin Ophthalmol; 2012; 6():103-9. PubMed ID: 22275814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of open-angle glaucoma and ocular hypertension with preservative-free tafluprost/timolol fixed-dose combination therapy: 6 case reports and clinical outcomes.
    Ansari E; Chappiti S; Pavicic-Astalos J; Pinto-Bonilla JC; Riva I; Sacchi M; Saénz-Francés F
    BMC Ophthalmol; 2022 Apr; 22(1):152. PubMed ID: 35366846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
    Uusitalo H; Chen E; Pfeiffer N; Brignole-Baudouin F; Kaarniranta K; Leino M; Puska P; Palmgren E; Hamacher T; Hofmann G; Petzold G; Richter U; Riedel T; Winter M; Ropo A
    Acta Ophthalmol; 2010 May; 88(3):329-36. PubMed ID: 20546237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Objective ocular surface tolerance in patients with glaucoma treated with topical preserved or unpreserved prostaglandin analogues.
    El Ameen A; Vandermeer G; Khanna RK; Pisella PJ
    Eur J Ophthalmol; 2019 Nov; 29(6):645-653. PubMed ID: 30301370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study.
    Bourne RRA; Kaarniranta K; Lorenz K; Traverso CE; Vuorinen J; Ropo A
    BMJ Open; 2019 Apr; 9(4):e024129. PubMed ID: 30944129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost.
    Hommer A; Kimmich F
    Clin Ophthalmol; 2011; 5():623-31. PubMed ID: 21629567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of changing from preserved prostaglandins to preservative-free tafluprost in patients with glaucoma on tear film thickness.
    Hommer A; Schmidl D; Kromus M; Bata AM; Fondi K; Werkmeister RM; Baar C; Schmetterer L; Garhöfer G
    Eur J Ophthalmol; 2018 Jul; 28(4):385-392. PubMed ID: 29592773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride.
    Wong TT; Aung T; Ho CL
    Clin Exp Ophthalmol; 2018 Dec; 46(9):1028-1034. PubMed ID: 29802759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 24-Hour Evaluation of the Effectiveness and Tolerability of Preservative-Free Tafluprost-Timolol Fixed Combination in Open-Angle Glaucoma or Ocular Hypertensive Patients Previously Treated with Preserved Latanoprost.
    Oddone F; Tanga L; Giammaria S; Sabbatini L; Strianese A; Ferrazza M; Rossetti LM
    Clin Ophthalmol; 2024; 18():1751-1760. PubMed ID: 38919404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension.
    Whitson JT; Trattler WB; Matossian C; Williams J; Hollander DA
    J Ocul Pharmacol Ther; 2010 Jun; 26(3):287-92. PubMed ID: 20578283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, Safety and Patient-Reported Outcomes with Preservative-Free (PF) Tafluprost or PF-Dorzolamide/Timolol Compared with Preserved Latanoprost: A Prospective Multicenter Study in Korean Glaucoma Patients with Ocular Surface Disease.
    Park SW; Lee J; Kook MS
    Pharmaceuticals (Basel); 2022 Feb; 15(2):. PubMed ID: 35215313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of a Preservative-Free Latanoprost Cationic Emulsion in Patients with Open-Angle Glaucoma and Concurrent Ocular Surface Disease: A Randomized Phase 2 Study.
    Bacharach J; McLaurin EB; Silverstein S; Amrane M; Garrigue JS; Ismail D; Flynn WJ;
    J Ocul Pharmacol Ther; 2024 Aug; ():. PubMed ID: 39150378
    [No Abstract]   [Full Text] [Related]  

  • 17. Long term safety and tolerability of Tafluprost 0.0015% vs Timolol 0.1% preservative-free in ocular hypertensive and in primary open-angle glaucoma patients: a cross sectional study.
    Rolle T; Spinetta R; Nuzzi R
    BMC Ophthalmol; 2017 Aug; 17(1):136. PubMed ID: 28768500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tear clearance and ocular symptoms in patients treated with preservative-free prostaglandins.
    Giménez-Gómez R; García-Catalán MR; Gallardo-Galera JM
    Arch Soc Esp Oftalmol; 2013 Mar; 88(3):88-91. PubMed ID: 23473084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in Ocular Surface Characteristics after Switching from Benzalkonium Chloride-Preserved Latanoprost to Preservative-Free Tafluprost or Benzalkonium Chloride-Preserved Tafluprost.
    Tokuda N; Kitaoka Y; Matsuzawa A; Tsukamoto A; Sase K; Sakae S; Takagi H
    J Ophthalmol; 2017; 2017():3540749. PubMed ID: 28831305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Pooled Assessment of Ocular Surface Disease After Switching from Preserved Prostaglandins to Tafluprost Across Six Countries in Asia.
    Tumbocon JA; Wong TT; Sangapillai T; Yen YC; Park SW; Lim HH; Ruangvaravate N
    Clin Ophthalmol; 2022; 16():2669-2676. PubMed ID: 35999967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.